KRAS and non-small cell lung carcinoma: The consensus of the experts was that there is sufficient evidence to test not only for EGFR mutations and ALK rearrangements/fusions, but that all patients with advanced-stage non-squamous NSCLC should be tested for PD-L1 protein expression with IHC and for alterations associated with BRAF, ERBB2, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, and ROS1 (Table 1).